Theseus Pharmaceuticals (THRX) has released an update.
Theseus Pharmaceuticals has successfully completed its merger with Concentra Biosciences, after Concentra’s subsidiary acquired the majority of Theseus’s shares. Shareholders were offered $4.05 per share in cash, plus the opportunity for future payments through a contingent value right. The takeover resulted in Theseus becoming a wholly owned subsidiary of Concentra, leading to the delisting of Theseus’s shares from the Nasdaq and the termination of its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. The transaction, which did not require a stockholder vote, signifies a significant shift in Theseus’s corporate structure and stock market presence.
For further insights into THRX stock, check out TipRanks’ Stock Analysis page.